Your browser doesn't support javascript.
loading
Type 1 diabetes.
Quattrin, Teresa; Mastrandrea, Lucy D; Walker, Lucy S K.
Afiliação
  • Quattrin T; Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Diabetes Center, John R Oishei Children's Hospital, Buffalo, NY, USA. Electronic address: tquattrin@upa.chob.edu.
  • Mastrandrea LD; Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Diabetes Center, John R Oishei Children's Hospital, Buffalo, NY, USA.
  • Walker LSK; Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
Lancet ; 401(10394): 2149-2162, 2023 06 24.
Article em En | MEDLINE | ID: mdl-37030316
ABSTRACT
Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic ß cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced knowledge related to the pathophysiology of the disease, including interactions between genetic, immune, and environmental contributions, and major strides in treatment and management, disease burden remains high. Studies aimed at blocking the immune attack on ß cells in people at risk or individuals with very early onset type 1 diabetes show promise in preserving endogenous insulin production. This Seminar will review the field of type 1 diabetes, highlighting recent progress within the past 5 years, challenges to clinical care, and future directions in research, including strategies to prevent, manage, and cure the disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Células Secretoras de Insulina Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 / Células Secretoras de Insulina Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article